Trial Profile
A Crossover Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Filorexant (Primary) ; MK 1064 (Primary)
- Indications Insomnia
- Focus Adverse reactions; Therapeutic Use
- Acronyms MK-1064-003
- Sponsors Merck Sharp & Dohme
- 22 Sep 2015 New trial record